Ehealth (M5V) Q2 2026 Earnings Report

The call presented a balanced mix of strong operational progress and short-term financial headwinds. Positive developments include the launch of the lifetime advisory model with encouraging early cross-sell results, meaningful cost reductions, substantial quarterly cash flow improvement, AI-driven efficiency gains, and maintained guidance with a roadmap to return to growth in 2027. Offsetting these positives are steep year-over-year declines in Q2 revenue (down 45%), compressed Medicare gross profit (down ~68.6%), deeper GAAP and adjusted EBITDA losses, lower tail revenue, and higher per-member customer care costs. Management expects additional near-term revenue headwinds due to planned marketing reductions before re-allocating spend into Q4. Overall, the call signals progress on restructuring and cash-flow improvement but continued short-term operational and revenue challenges.

Management said it is maintaining its 2026 guidance ranges for revenue, GAAP net income, adjusted EBITDA and operating cash flow while updating 2026 net adjustment (tail) revenue to $16–$20 million, and reiterated a goal of break‑even or better operating cash flow at the midpoint of guidance (with year‑over‑year operating cash flow improvement expected in each remaining quarter and positive operating cash flow targeted in 2027). They forecast annual variable cost savings of >$60 million and fixed cost savings of ~$30 million, will cut Q3 marketing spend even more than the 45% y/y reduction in Q2 and deploy the bulk of marketing in Q4, and expect ICHRA revenue to remain below $5 million in 2026. Liquidity and operating datapoints cited included $101 million of cash and short‑term marketable securities, $1.0 billion of commission receivables (+10% y/y), cumulative tail revenue of $284 million since 2018, and Q2 results of $33.6 million revenue, GAAP net loss $23.6 million, adjusted EBITDA loss $21.8 million and Q2 operating cash flow of negative $5 million.